Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 9/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21135295 | 0.90 | STAT3 (0.50) | CHEK1PIK3CDMTORPIK3CASTAT3 | |
| SCHEMBL21135294 | 0.89 | MAPT (0.44) | PIK3CDMTORPIK3CAPIK3CGSTAT3 | |
| SCHEMBL21135270 | 0.83 | PTPN11 (0.47) | CHEK1PIK3CDAKT1MTORPIK3CA | |
| SCHEMBL30312366 | 0.81 | PIKFYVE (0.58) | CHEK1PIK3CDAKT1MTORPIK3CA | |
| SCHEMBL21054341 | 0.81 | PIKFYVE (0.58) | CHEK1PIK3CDAKT1MTORPIK3CA | |
| SCHEMBL21135489 | 0.75 | PIK3CD (0.64) | PIK3CDPIK3CGSTAT3 | |
| SCHEMBL21135197 | 0.75 | PIK3CD (0.52) | PIK3CDPIK3CG | |
| SCHEMBL21135863 | 0.73 | PIK3CD (0.51) | PIK3CDPIK3CG | |
| SCHEMBL21135404 | 0.73 | PIK3R1 (0.51) | MTORPIK3CASTAT3 | |
| SCHEMBL21135293 | 0.72 | MAPT (0.46) | PIK3CDMTORPIK3CAPIK3CGSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019113523-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | BAJJI ASHOK (US) | 2019-06-13 | — | — | WO | disclosed |